✦ LIBER ✦

PCN58 A COST UTILITY ANALYSIS OF ERLOTINIB IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)

✍ Scribed by PA Bradbury; R Jang; P Isogai; R Ng; N Mittmann; W Evans; FA Shepherd; NB Leighl

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN77 COST-EFFECTIVENESS ANALYSIS OF ERL

✍ TE Ciuleanu; M Dediu; LN Minea; S Baculea; M Szkultecka-Debek 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

Clinical efficacy of erlotinib in patien

✍ Songwen ZHOU; Shengxiang REN; Lianghua YAN; Ling ZHANG; Liang TANG; Jie ZHANG; C 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 496 KB

Erlotinib in a previously treated advanc

✍ C. Gridelli; A. Rossi; P. Maione; C. Ferrara; F. Del Gaizo; D. Nicolella; C. Gue 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 91 KB

A phase II study of enzastaurin in combi

✍ Clément-Duchêne, Christelle; Natale, Ronald B.; Jahan, Thierry; Krupitskaya, Yel 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 300 KB

Clinical surrogate markers of survival i

✍ Cedrés, Susana; Prat, Aleix; Martínez, Pablo; Pallisa, Esther; Sala, Gemma; Andr 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 341 KB

Erlotinib treatment results in patients

✍ Salajka, F.; Pešek, M.; Skřičková, J.; Zatloukal, P.; Koubková, L.; Grygárková, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB